Theratechnologies (TSE:TH) Sets New 12-Month High - Should You Buy?

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.54 during trading, though the stock was last traded at C$4.54 after a previous close of C$4.59.
• Analysts have mixed opinions on the stock, with Jones Trading downgrading it from a "strong-buy" to a "hold," while the consensus rating remains a "Buy."
• The company specializes in pharmaceutical products for HIV patients and has a market cap of C$207.83 million, with a notable debt-to-equity ratio of -293.92.

Theratechnologies Inc. (TSE:TH - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as C$4.54 and last traded at C$4.54, with a volume of 3537 shares changing hands. The stock had previously closed at C$4.59.

Analyst Upgrades and Downgrades

Separately, Jones Trading downgraded shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy".

Theratechnologies Price Performance

The company has a debt-to-equity ratio of -293.92, a current ratio of 1.08 and a quick ratio of 0.64. The stock has a market cap of C$208.29 million, a P/E ratio of -23.84, a P/E/G ratio of -8.50 and a beta of 0.26. The company's 50 day simple moving average is C$4.42 and its 200 day simple moving average is C$3.59.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.